12/08/2026
A New Med & New Class of Med for ADHD just FDA approved for ADHD in Kids, Teens & Adults: yep, another new option for ADHD in all age groups has arrived, coming to local Pharmacies by late 2026 or early 2027, pending DEA review of stimulant-type meds. Simtriyo will be the brand name of Centanafine, a novel new class of a “TRIO” of brain neurotransmitter (NE & DA & 5HT) reuptake inhibitors, now called NDS-RI. Early studies show improvement in classic ADHD symptoms (DA & NE effects) + anxiety symptoms (5HT effect), but sadly LESS powerful & LESS immediate acting than Stimulant meds, so more like weaker current Non-Stimulants Strattera (Atomoxetine) & Qelbree (Viloxazine). Stay tuned. Call or write use for more information. We are here for ya !